Compare ANNX & UVSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | UVSP |
|---|---|---|
| Founded | 2011 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.2M | 910.5M |
| IPO Year | 2020 | 1989 |
| Metric | ANNX | UVSP |
|---|---|---|
| Price | $5.64 | $35.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | $16.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.3M | 150.4K |
| Earning Date | 03-02-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | ★ 21.32 |
| EPS | N/A | ★ 3.13 |
| Revenue | N/A | ★ $316,389,000.00 |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $5.75 |
| P/E Ratio | ★ N/A | $11.32 |
| Revenue Growth | N/A | ★ 7.88 |
| 52 Week Low | $1.29 | $22.83 |
| 52 Week High | $7.18 | $36.00 |
| Indicator | ANNX | UVSP |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 63.88 |
| Support Level | $6.10 | $32.46 |
| Resistance Level | $6.59 | $36.00 |
| Average True Range (ATR) | 0.43 | 1.03 |
| MACD | -0.14 | 0.20 |
| Stochastic Oscillator | 10.57 | 82.20 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.